{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:44:31Z","timestamp":1792313071047,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Targeted therapies have been shown to improve outcomes in metastatic non\u2010small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real\u2010world prevalence of human epidermal growth factor receptor 2 (HER2; <jats:italic>ERBB2<\/jats:italic>) tumor gene mutations among patients with mNSCLC and described historical treatments and outcomes in patients with <jats:italic>HER2<\/jats:italic>\u2010mutant mNSCLC, during a period when there was no approved targeted therapy for <jats:italic>HER2<\/jats:italic>\u2010mutant mNSCLC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This retrospective observational study used a US nationwide de\u2010identified NSCLC clinico\u2010genomic database. Eligible patients were adults diagnosed with <jats:italic>HER2<\/jats:italic>\u2010mutant mNSCLC from January 2014 to July 2021 without co\u2010occuring epidermal growth factor receptor (<jats:italic>EGFR<\/jats:italic>) tumor mutations. Descriptive statistics were used to summarize prevalence, baseline characteristics and treatment patterns. Clinical outcomes were estimated with Kaplan\u2013Meier analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 9206 patients with mNSCLC, 164 (1.78%) met the eligibility criteria (mean age: 67.3\u2009years, 63.4% White, 56.7% female, and 53.0% with a smoking history). 132\/164 (80.5%) had at least one line of treatment. Platinum\u2010based chemotherapy (45.5%) and immune checkpoint inhibitor (ICI) with chemotherapy (28.0%) were the most frequently used first\u2010line treatments. The median (95% confidence interval [CI]) real\u2010world (rw) progression\u2010free survival in first\u2010line was 5.5 (4.8, 6.2) months and 3.0 (2.3, 4.2) months in second\u2010line. The median rw overall survival in first\u2010line was 13.2 (10.6, 18.4) months and 8.2 (6.6, 13.2) months in second\u2010line.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>During this study period, the most common regimens were platinum\u2010based chemotherapy with or without ICI in first and second line, and median rwOS was 13.2 and 8.2\u2009months, respectively. These results indicate the need for more effective targeted therapies in this patient population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70272","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:39:38Z","timestamp":1734536378000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real\u2010World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (<i>ERBB2<\/i>)\u2010Mutant Metastatic Non\u2010Small Cell Lung Cancer, From a US\u2010Based Clinico\u2010Genomic Database"],"prefix":"10.1002","volume":"13","author":[{"given":"Sarah","family":"Waliany","sequence":"first","affiliation":[{"name":"Department of Medicine Massachusetts General Hospital Cancer Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[{"name":"University of California Irvine School of Medicine  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-6265","authenticated-orcid":false,"given":"Leah","family":"Park","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Lam","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Jiang","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-0420","authenticated-orcid":false,"given":"Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo  Basking Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-9334","authenticated-orcid":false,"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[{"name":"Department of Medicine Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Cancer.net \u201cLung Cancer\u2014Non\u2010Small Cell: Statistics \u201d2023 https:\/\/www.cancer.net\/cancer\u2010types\/lung\u2010cancer\u2010non\u2010small\u2010cell\/statistics."},{"key":"e_1_2_10_3_1","unstructured":"American Cancer Society \u201cNon\u2010Small Cell Lung Cancer Survival Rates \u201d2022 https:\/\/www.cancer.org\/cancer\/lung\u2010cancer\/detection\u2010diagnosis\u2010staging\/survival\u2010rates.html."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7293"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.09.010"},{"issue":"4785","key":"e_1_2_10_11_1","first-page":"177","article-title":"Amplification of a Novel v\u2010erbB\u2010Related Gene in a Human Mammary Carcinoma","volume":"235","author":"King C. R.","year":"1987","journal-title":"Science"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9552-6"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30869"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24958"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101996"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00004-0"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy554"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2217\/lmt-2020-0003"},{"key":"e_1_2_10_22_1","unstructured":"FDA \u201cFDA Grants Accelerated Approval to Fam\u2010Trastuzumab Deruxtecan\u2010Nxki for HER2\u2010Mutant Non\u2010Small Cell Lung Cancer \u201d2022 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010fam\u2010trastuzumab\u2010deruxtecan\u2010nxki\u2010her2\u2010mutant\u2010non\u2010small\u2010cell\u2010lung."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.10.032"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.021"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.057"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.09.026"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh031"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21428"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00215-2"},{"key":"e_1_2_10_33_1","unstructured":"ENHERTU \u201c(Fam\u2010Trastuzumab Deruxtecan\u2010Nxki) for Injection for Intravenous Use Initial U.S. Approval: 2019 2019 \u201d2022."},{"key":"e_1_2_10_34_1","unstructured":"Daiichi\u2010Sankyo \u201cENHERTU Approved in the U.S as the First HER2 Directed Therapy for Patients With Previously Treated HER2 Mutant Metastatic Non\u2010Small Cell Lung Cancer \u201d2023."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6095"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.05.015"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv573"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22442"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32461"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.129"},{"key":"e_1_2_10_42_1","first-page":"6090","article-title":"PD\u2010L1 Expression, Tumor Mutation Burden and Response to Immune Checkpoint Blockade in Patients With HER2\u2010Mutant Lung Cancers","volume":"36","author":"Wei\u2010Chu V. L.","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9137"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.105"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107315"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9777"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T08:56:42Z","timestamp":1738918602000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/cam4.70272"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70272","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"2024-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70272"}}